Privia Health Group, Inc. (NASDAQ:PRVA) Shares Sold by Ironwood Investment Counsel LLC

Ironwood Investment Counsel LLC lowered its stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 50.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,137 shares of the company’s stock after selling 17,138 shares during the quarter. Ironwood Investment Counsel LLC’s holdings in Privia Health Group were worth $336,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Advisors Preferred LLC purchased a new stake in Privia Health Group in the fourth quarter valued at $2,137,000. Riverbridge Partners LLC lifted its holdings in shares of Privia Health Group by 8.7% in the 4th quarter. Riverbridge Partners LLC now owns 4,342,385 shares of the company’s stock valued at $100,005,000 after purchasing an additional 348,852 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its position in shares of Privia Health Group by 27.1% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 234,991 shares of the company’s stock valued at $4,603,000 after purchasing an additional 50,042 shares during the period. Vanguard Group Inc. grew its stake in Privia Health Group by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 11,003,989 shares of the company’s stock worth $253,092,000 after buying an additional 51,317 shares during the last quarter. Finally, Handelsbanken Fonder AB grew its stake in Privia Health Group by 41.5% during the 4th quarter. Handelsbanken Fonder AB now owns 15,000 shares of the company’s stock worth $345,000 after buying an additional 4,400 shares during the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Privia Health Group Stock Up 2.3 %

Shares of Privia Health Group stock traded up $0.44 during trading on Monday, reaching $19.61. The company’s stock had a trading volume of 653,839 shares, compared to its average volume of 931,275. The business has a 50 day moving average price of $17.34 and a 200-day moving average price of $19.15. Privia Health Group, Inc. has a 12-month low of $15.92 and a 12-month high of $28.10. The company has a market capitalization of $2.34 billion, a P/E ratio of 130.73, a price-to-earnings-growth ratio of 3.00 and a beta of 0.78.

Privia Health Group (NASDAQ:PRVA) last issued its earnings results on Thursday, May 9th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.03). The company had revenue of $415.24 million for the quarter, compared to analysts’ expectations of $435.07 million. Privia Health Group had a return on equity of 3.13% and a net margin of 1.11%. Research analysts predict that Privia Health Group, Inc. will post 0.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PRVA has been the subject of several research analyst reports. Robert W. Baird started coverage on Privia Health Group in a report on Thursday, May 30th. They issued an “outperform” rating and a $23.00 price objective for the company. Citigroup started coverage on shares of Privia Health Group in a research report on Monday, April 22nd. They set a “buy” rating and a $25.00 price objective on the stock. Evercore ISI reduced their target price on shares of Privia Health Group from $23.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, July 9th. Barclays lowered their price target on Privia Health Group from $22.00 to $19.00 and set an “equal weight” rating on the stock in a report on Monday, May 20th. Finally, Canaccord Genuity Group decreased their price objective on Privia Health Group from $37.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, May 10th. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Privia Health Group has an average rating of “Moderate Buy” and an average target price of $24.54.

Insider Buying and Selling at Privia Health Group

In other news, Director Adam Boehler acquired 277,565 shares of Privia Health Group stock in a transaction that occurred on Tuesday, May 21st. The stock was purchased at an average cost of $16.17 per share, with a total value of $4,488,226.05. Following the completion of the acquisition, the director now owns 5,488,701 shares in the company, valued at approximately $88,752,295.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Thomas A. Mccarthy bought 10,000 shares of Privia Health Group stock in a transaction that occurred on Thursday, May 23rd. The shares were purchased at an average price of $16.37 per share, with a total value of $163,700.00. Following the purchase, the director now owns 52,611 shares in the company, valued at $861,242.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Adam Boehler acquired 277,565 shares of the firm’s stock in a transaction that occurred on Tuesday, May 21st. The shares were bought at an average cost of $16.17 per share, for a total transaction of $4,488,226.05. Following the purchase, the director now owns 5,488,701 shares of the company’s stock, valued at $88,752,295.17. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 293,235 shares of company stock valued at $4,745,481 and sold 45,457 shares valued at $827,810. 14.20% of the stock is currently owned by corporate insiders.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.